Switch theme
Sign up to access all valuation multiples
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company generates a majority of its revenue from Taiwan and the rest from the United States.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tanvex BioPharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Tanvex BioPharma achieved revenue of $1.0M and an EBITDA of -$31.4M.
Tanvex BioPharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tanvex BioPharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $1.9M | $1.0M | XXX | XXX | XXX |
| Gross Profit | -$0.6M | $1.8M | XXX | XXX | XXX |
| Gross Margin | -32% | 172% | XXX | XXX | XXX |
| EBITDA | -$53.0M | -$31.4M | XXX | XXX | XXX |
| EBITDA Margin | -2857% | -2996% | XXX | XXX | XXX |
| Net Profit | -$49.6M | -$64.5M | XXX | XXX | XXX |
| Net Margin | -2672% | -6163% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Tanvex BioPharma's stock price is TWD 60 (or $2).
Tanvex BioPharma has current market cap of TWD 9.8B (or $296M), and EV of TWD 11.1B (or $335M).
See Tanvex BioPharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $335M | $296M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Tanvex BioPharma has market cap of $296M and EV of $335M.
Tanvex BioPharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Tanvex BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Tanvex BioPharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $335M | XXX | XXX | XXX |
| EV/Revenue | 319.6x | XXX | XXX | XXX |
| EV/EBITDA | -10.7x | XXX | XXX | XXX |
| P/E | -7.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -8.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTanvex BioPharma's NTM/LTM revenue growth is n/a
Tanvex BioPharma's revenue per employee for the last fiscal year averaged $6K, while opex per employee averaged $0.2M for the same period.
Over next 12 months, Tanvex BioPharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Tanvex BioPharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Tanvex BioPharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -44% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -2996% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -41% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $6K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 129% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 755% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3052% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 3936% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tanvex BioPharma acquired XXX companies to date.
Last acquisition by Tanvex BioPharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Tanvex BioPharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Tanvex BioPharma founded? | Tanvex BioPharma was founded in 2013. |
| Where is Tanvex BioPharma headquartered? | Tanvex BioPharma is headquartered in Taiwan. |
| How many employees does Tanvex BioPharma have? | As of today, Tanvex BioPharma has 183 employees. |
| Who is the CEO of Tanvex BioPharma? | Tanvex BioPharma's CEO is Mr. Lin-Cheng Chen. |
| Is Tanvex BioPharma publicy listed? | Yes, Tanvex BioPharma is a public company listed on TAI. |
| What is the stock symbol of Tanvex BioPharma? | Tanvex BioPharma trades under 6541 ticker. |
| When did Tanvex BioPharma go public? | Tanvex BioPharma went public in 2015. |
| Who are competitors of Tanvex BioPharma? | Similar companies to Tanvex BioPharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Tanvex BioPharma? | Tanvex BioPharma's current market cap is $296M |
| What is the current revenue growth of Tanvex BioPharma? | Tanvex BioPharma revenue growth between 2023 and 2024 was -44%. |
| Is Tanvex BioPharma profitable? | Yes, Tanvex BioPharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
